First Quarter 2025 Results

Bayer Q1 2025 Media Update

Group sales at 13.738 billion euros (Fx & p adj. minus 0.1 percent)
EBITDA before special items decreases to 4.085 billion euros (minus 7.4 percent)
Moderate decline in sales (Fx & p adj.) at Crop Science, earnings down year on year
Pharmaceuticals posts higher sales, earnings significantly above prior-year level
Sales and earnings up at Consumer Health
Core earnings per share at 2.49 euros (minus 11.7 percent)
Net income at 1.299 billion euros
Free cash flow improves to minus 1.528 billion euros
Net financial debt at 34.255 billion euros
Currency-adjusted Group outlook confirmed
Execution of five-year plan for Crop Science under way